AMGEN has announced changes to its controversial direct-to-pharmacy distribution model for Prolia, as part of its "ongoing commitment to work closely with community pharmacy to provide support through the transition".
Effective this month, Amgen confirmed it would remove Prolia (denusomab) from the major CSO pharmaceutical distributors, instead requiring pharmacies to order direct via DHL (PD 23 Nov).
The company has received significant feedback from pharmacies, and overnight announced changes to the commercial offer including free delivery for second monthly orders of 1-3 units of Prolia.
"This change reflects Amgen's efforts to better support pharmacies that may have smaller order requirements," Amgen said.
Additional discounts will also now be offered on larger orders effective from 01 Jan, with 4-16 units of Prolia receiving a 2% discount (was 1.5%), and orders of 17+ units discounted by 2.8% (up from 2.5%).
"Ordering has been progressing very well, with almost 10% of community pharmacies using the DHL Direct to Market Service to order Prolia on the first day it came into effect, December 1," said Amgen Australia md My Linh Kha.
"We remain committed to working with community pharmacy and providing support during this transition period, and over the longer term as we build a partnership to support improved outcomes for patients with osteoporosis," Kha said.
The above article was sent to subscribers in Pharmacy Daily's issue from 12 Dec 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Dec 17
